Failure to Satisfy Listing Rule (Form 8-K)

As previously disclosed, on May 8, 2025, Accelerate Diagnostics, Inc. (the "Company") and certain of its subsidiaries (together, the "Debtors") filed voluntary petitions (the "Bankruptcy Petitions") under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the "Court" and such cases, the "Cases").

On May 8, 2025, the Company received written notice (the "Delisting Notice") from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, as a result of the Bankruptcy Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the Staff has determined that the Company's common stock (the "Securities") will be delisted from Nasdaq. In addition, on May 6, 2025, the Company received written notice from the Staff notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock had closed below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").

In the Delisting Notice, the Staff stated that its determination was based on (i) public interest concerns related to the Bankruptcy Petitions, (ii) concerns regarding the residual equity interest of the existing holders of listed Securities and (iii) concerns about the Company's ability to sustain compliance with all requirements for continued listing on Nasdaq. Specifically, the Staff noted that the Company was not in compliance with the Minimum Bid Price Requirement, nor in compliance with Nasdaq's Market Value of Listed Securities (as defined under Nasdaq rules) requirement pursuant to Nasdaq Listing Rule 5550(b)(2) (the "MVLS Requirement"), as previously disclosed in the Company's Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the "SEC") on January 30, 2025. As a result, the Staff determined that the Company's Minimum Bid Price Requirement and MVLS Requirement deficiencies served as an additional and separate basis for delisting.

The Delisting Notice also indicates that the Company may appeal Nasdaq's determination pursuant to procedures set forth in the Nasdaq Listing Rule 5800 Series. The Company does not intend to appeal the determination and, therefore, it is expected that the Securities will be delisted.

Trading of the Securities will be suspended at the opening of business on May 15, 2025 and a Form 25-NSE will be filed by Nasdaq with the SEC, which will remove the Securities from listing and registration on Nasdaq. The Company expects the Securities will begin trading on the over-the-counter (the "OTC") market under the symbol "AXDXQ" on May 15, 2025, but no assurance can be made that trading in the Securities on the OTC market will commence or be maintained.